A
ABBV
ABBVUnverified24 segments tracked|6 years of data|Annual (10-K)
Total Revenue
$51.9B3.8%
FY2024
Operating Segments
24Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%SKYRIZI
Segment Shift
SKYRIZI has grown from 1.2% to 22.6% of total revenue since FY2019, with 0.0% operating margins. Meanwhile, Epkinly is the fastest growing at +371.0% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| SKYRIZI | $11.7B | $0 | 0.0% | 22.6% | +50.9% |
| HUMIRA | $9.0B | $0 | 0.0% | 17.3% | -37.6% |
| RINVOQ | $6.0B | $0 | 0.0% | 11.5% | +50.4% |
| Imbruvica | $3.3B | $0 | 0.0% | 6.4% | -6.9% |
| Botox Therapeutic | $3.3B | $0 | 0.0% | 6.3% | +9.8% |
| Vraylar | $3.3B | $0 | 0.0% | 6.3% | +18.4% |
| Botox Cosmetic | $2.7B | $0 | 0.0% | 5.2% | +1.4% |
| VENCLEXTA | $2.6B | $0 | 0.0% | 5.0% | +12.9% |
| MAVYRET | $1.3B | $0 | 0.0% | 2.5% | -8.3% |
| Other Aesthetics | $1.3B | $0 | 0.0% | 2.5% | +3.6% |
| Juvederm Collection | $1.2B | $0 | 0.0% | 2.3% | -14.6% |
| Ubrelvy | $1.0B | $0 | 0.0% | 1.9% | +23.4% |
| Linzess Constella | $954M | $0 | 0.0% | 1.8% | -13.9% |
| Other Eye Care | $847M | $0 | 0.0% | 1.6% | +5.5% |
| Qulipta | $658M | $0 | 0.0% | 1.3% | +61.3% |
| Ozurdex | $494M | $0 | 0.0% | 1.0% | +4.7% |
| Elahere | $479M | $0 | 0.0% | 0.9% | +0.0% |
| Duodopa | $447M | $0 | 0.0% | 0.9% | -4.5% |
| Lumigan Ganfort | $429M | $0 | 0.0% | 0.8% | -0.7% |
| Other Neuroscience | $338M | $0 | 0.0% | 0.7% | +22.5% |
| Alphagan Combigan | $248M | $0 | 0.0% | 0.5% | -8.8% |
| Restasis | $224M | $0 | 0.0% | 0.4% | -48.6% |
| Epkinly | $146M | $0 | 0.0% | 0.3% | +371.0% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free